Analytical Data
-
Gene name
Icarapin
- Application
-
Alternative Names
Venom protein 2 Allergen: Api m 10
-
Species
Apis mellifera carnica
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5EF78
-
Expression Region
20-223aa
-
Molecular Weight
27.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Icarapin, a recombinant protein derived from the venom of the Chinese red-headed centipede (Scolopendra subspinipes), has garnered significant attention in biomedical research due to its potential therapeutic applications. Centipede venom is known for its complex mixture of bioactive compounds, which have evolved to possess various pharmacological properties, including antimicrobial, anti-inflammatory, and analgesic effects. The interest in Icarapin is primarily driven by its unique ability to modulate immune responses and its potential to act as an immunomodulatory agent. Studies have demonstrated that Icarapin can interact with immune cells, potentially enhancing their function and promoting the body’s defense mechanisms against infections. Furthermore, its recombinant form allows for more controlled studies, as well as the possibility of large-scale production, which is crucial for clinical applications. As researchers continue to explore the mechanism of action and the therapeutic potential of Icarapin, it could pave the way for novel treatments in infectious diseases, autoimmune disorders, and other conditions where immune regulation is critical. This makes Icarapin a promising candidate in the field of biopharmaceuticals, with the potential to address unmet medical needs through innovative therapeutic strategies.
